Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
- Craig Gedye,
- Juliet Quirk,
- Judy Browning,
- Suzanne Svobodová,
- Thomas John,
- Pavel Sluka,
- P. Rod Dunbar,
- Denis Corbeil,
- Jonathan Cebon,
- Ian D. Davis
- … show all 10 hide
Rent the article at a discount
Rent now* Final gross prices may vary according to local VAT.
Get AccessAbstract
“Cancer stem cells” that resist conventional treatments may be a cause of therapeutic failure in melanoma. We report a subpopulation of clonogenic melanoma cells that are characterized by high prominin-1/CD133 expression in melanoma and melanoma cell lines. These cells have enhanced clonogenicity and self-renewal in vitro, and serve as a limited in vitro model for melanoma stem cells. In some cases clonogenic CD133+ melanoma cells show increased expression of some cancer/testis (CT) antigens. The expression of NY-ESO-1 in an HLA-A2 expressing cell line allowed CD133+ clonogenic melanoma cells to be targeted for killing in vitro by NY-ESO-1-specific CD8+ T-lymphocytes. Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma.
- blah 262_2009_672_MOESM1_ESM.pdf (1401KB)
- Thompson, JF, Scolyer, RA, Kefford, RF (2005) Cutaneous melanoma. Lancet 365: pp. 687-701
- Phan, GQ, Yang, JC, Sherry, RM (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: pp. 8372-8377 CrossRef
- Morgan, RA, Dudley, ME, Wunderlich, JR (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: pp. 126-129 CrossRef
- Cebon, J, Gedye, C, John, T (2007) Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 5: pp. 994-1006
- Reya, T, Morrison, SJ, Clarke, MF (2001) Stem cells, cancer, and cancer stem cells. Nature 414: pp. 105-111 CrossRef
- Dalerba, P, Cho, RW, Clarke, MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: pp. 267-284 CrossRef
- Polyak, K, Hahn, WC (2006) Roots and stems: stem cells in cancer. Nat Med 12: pp. 296-300 CrossRef
- Brabletz, T, Jung, A, Spaderna, S (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5: pp. 744-749 CrossRef
- Kim, JJ, Tannock, IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: pp. 516-525 CrossRef
- Frank, NY, Margaryan, A, Huang, Y (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: pp. 4320-4333 CrossRef
- Fang, D, Nguyen, TK, Leishear, K (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: pp. 9328-9337 CrossRef
- Klein, WM, Wu, BP, Zhao, S (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: pp. 102-107 CrossRef
- Monzani, E, Facchetti, F, Galmozzi, E (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: pp. 935-946 CrossRef
- Schatton, T, Murphy, GF, Frank, NY (2008) Identification of cells initiating human melanomas. Nature 451: pp. 345-349 CrossRef
- Quintana, E, Shackleton, M, Sabel, MS (2008) Efficient tumour formation by single human melanoma cells. Nature 456: pp. 593-598 CrossRef
- Scanlan, MJ, Simpson, AJ, Old, LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4: pp. 1
- Nicholaou, T, Ebert, L, Davis, ID (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 84: pp. 303-317 CrossRef
- Simpson, AJ, Caballero, OL, Jungbluth, A (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: pp. 615-625 CrossRef
- Jäger, D, Taverna, C, Zippelius, A (2004) Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 53: pp. 144-147 CrossRef
- Yang, B, O’Herrin, SM, Wu, J (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67: pp. 9954-9962 CrossRef
- Laduron, S, Deplus, R, Zhou, S (2004) MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32: pp. 4340-4350 CrossRef
- Cho, HJ, Caballero, OL, Gnjatic, S (2006) Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 6: pp. 12
- Davis, ID, Chen, W, Jackson, H (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101: pp. 10697-10702 CrossRef
- Fargeas, CA, Fonseca, A-V, Huttner, WB (2006) Prominin–1 (CD133): from progenitor cells to human diseases. Future Lipidol 1: pp. 213-225 CrossRef
- Singh, SK, Hawkins, C, Clarke, ID (2004) Identification of human brain tumour initiating cells. Nature 432: pp. 396-401 CrossRef
- Belicchi, M, Pisati, F, Lopa, R (2004) Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 77: pp. 475-486 CrossRef
- Gibbs, P, Hutchins, AM, Dorian, KT (2000) MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res 10: pp. 259-264 CrossRef
- Carey, TE, Takahashi, T, Resnick, LA (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 73: pp. 3278-3282 CrossRef
- Karbanova, J, Missol-Kolka, E, Fonseca, AV (2008) The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56: pp. 977-993 CrossRef
- Barrow, C, Browning, J, MacGregor, D (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12: pp. 764-771 CrossRef
- Jungbluth, AA, Chen, YT, Busam, KJ (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99: pp. 839-845 CrossRef
- Vaughan, HA, Svobodova, S, MacGregor, D (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10: pp. 8396-8404 CrossRef
- Chen, JL, Dunbar, PR, Gileadi, U (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 165: pp. 948-955
- Lev, DC, Onn, A, Melinkova, VO (2004) Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22: pp. 2092-2100 CrossRef
- Grichnik, JM, Burch, JA, Schulteis, RD (2006) Melanoma, a tumor based on a mutant stem cell?. J Invest Dermatol 126: pp. 142-153 CrossRef
- Clarke, MF (2005) A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56: pp. 64-68 CrossRef
- Jaksch, M, Munera, J, Bajpai, R (2008) Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 68: pp. 7882-7886 CrossRef
- Herlyn, M, Balaban, G, Bennicelli, J (1985) Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74: pp. 283-289
- Lee, J, Kotliarova, S, Kotliarov, Y (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: pp. 391-403 CrossRef
- Li, A, Walling, J, Kotliarov, Y (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6: pp. 21-30 CrossRef
- Witt Hamer, PC, Tilborg, AA, Eijk, PP (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27: pp. 2091-2096 CrossRef
- Vogl, A, Sartorius, U, Vogt, T (2005) Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. J Investig Dermatol 124: pp. 401-404 CrossRef
- Sigalotti, L, Covre, A, Zabierowski, S (2008) Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 215: pp. 287-291 CrossRef
- Gjerstorff, MF, Johansen, LE, Nielsen, O (2006) Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 94: pp. 1864-1873 CrossRef
- Adair SJ, Hogan KT (2008) Treatment of ovarian cancer cell lines with 5-aza–2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. doi:10.1007/s00262-008-0582-6
- Rappa, G, Fodstad, O, Lorico, A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: pp. 3008-3017 CrossRef
- Yu JS (2008) Inventor. CEDARS-SINAI MEDICAL CENTER; 8700 Beverly Boulevard, Los Angeles, CA 90048 assignee. Cancer stem cell antigen vaccines and methods. US patent WO/2008/039874, 3 April 2008. http://www.wipo.int/pctdb/en/wo.jsp?WO=2008039874&IA=US2007079600&DISPLAY=STATUS
- Smith, LM, Nesterova, A, Ryan, MC (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99: pp. 100-109 CrossRef
- Florek, M, Haase, M, Marzesco, AM (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319: pp. 15-26 CrossRef
- Ponta, H, Sherman, L, Herrlich, PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: pp. 33-45 CrossRef
- Frank M (2007) Inventor. The Brigham and Women’s Hospital, Inc., Boston, MA., assignee. ABCB5 positive mesenchymal stem cells as immunomodulators. US Patent WO/2007/143139, 31 May 2007. http://www.wipo.int/pctdb/en/wo.jsp?WO=2007143139
- Ménard, C, Martin, F, Apetoh, L (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57: pp. 1579-1587 CrossRef
- Mine T, Matsueda S, Li Y et al (2008) Breast cancer cells expressing stem cell markers CD44(+) CD24 (lo) are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother. doi:10.1007/s00262-008-0623-1
- Title
- Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
- Journal
-
Cancer Immunology, Immunotherapy
Volume 58, Issue 10 , pp 1635-1646
- Cover Date
- 2009-10-01
- DOI
- 10.1007/s00262-009-0672-0
- Print ISSN
- 0340-7004
- Online ISSN
- 1432-0851
- Publisher
- Springer-Verlag
- Additional Links
- Topics
- Keywords
-
- Melanoma
- Clonogenic
- CD133
- Cancer/testis antigen
- Industry Sectors
- Authors
-
- Craig Gedye (1)
- Juliet Quirk (1)
- Judy Browning (1)
- Suzanne Svobodová (1)
- Thomas John (1)
- Pavel Sluka (1)
- P. Rod Dunbar (2)
- Denis Corbeil (3)
- Jonathan Cebon (1)
- Ian D. Davis (1)
- Author Affiliations
-
- 1. Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, VIC, 3084, Australia
- 2. School of Biological Sciences, Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand
- 3. Tissue Engineering Laboratories, BIOTEC and DFG Research Center and Cluster of Excellence for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany